Posts Tagged ‘venous thromboembolism’

September 1st, 2013

Positive Results for Edoxaban in VTE/PE

Findings from the Hokusai-VTE trial of edoxaban

July 1st, 2013

New Anticoagulant Found Safe and Effective in Acute Venous Thromboembolism

In a large clinical trial the new oral anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was at least as effective as standard therapy and caused fewer bleeding complications in patients with acute venous thromboembolism (VTE). The results of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial are being presented today at […]

May 20th, 2013

Selections from Richard Lehman’s Literature Review: May 20th

This week’s topics include the safety and efficacy of sitagliptin for type 2 diabetes, use of glucocorticoids and the risk of VTE, and forced smoking abstinence.

March 26th, 2013

Should the Use of IVC Filters be Filtered Until We Have More Data?

There’s been a remarkable increase in the use of IVC filters, but what is the evidence base behind this mechanistically appealing approach?

March 18th, 2013

Vena Cava Filters: Little Evidence and Wide Variation in Use

Despite the absence of any evidence demonstrating benefit or showing how best to use them, vena cava filters (VCF) are used in most hospitals. Now a new study published in JAMA Internal Medicine suggests that this same lack of evidence results in an extremely broad rate of use in different hospitals. An accompanying viewpoint raises the […]

February 25th, 2013

Selections from Richard Lehman’s Literature Review: February 25th

This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.

December 10th, 2012

Selections from Richard Lehman’s Literature Review: December 10th

This week’s topics include a comparison of warfarin and new oral anticoagulants for managing AF and VTE, two studies of a monoclonal antibody to PCSK9 in patients with hypercholesterolemia, and more.

December 8th, 2012

Prolonged Anticoagulation with Apixaban Beneficial in Venous Thromboembolism

A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were presented at the annual meeting of the American Society […]

November 26th, 2012

Selections from Richard Lehman’s Literature Review: November 26th

This week’s topics include fish oil and postoperative AF, low-dose aspirin for preventing recurrent VTE, a long-term comparison of endovascular and open repair of abdominal aortic aneurysm, and more.

November 15th, 2012

In Acute VTE, Novel Oral Anticoagulants and Conventional Therapy Show Similar Efficacy

Novel oral anticoagulants and vitamin K antagonists offer similar protection against venous thromboembolism recurrence, according to a BMJ meta-analysis. However, one of the newer agents, rivaroxaban, seems to offer better protection against bleeding. The analysis included nine randomized controlled trials comparing apixaban, dabigatran, rivaroxaban, or ximelagatran (no longer on the market) with traditional vitamin K antagonists […]